Literature DB >> 27536400

Crystal structure of 6,7-dihy-droxy-6,7-di-hydro-3H-imidazo[1,2-a]purin-9(5H)-one.

Wei Guo1, Cheng-Xun Li1, Jie Lv1, Jing Wang1.   

Abstract

The title purine derivative, C7H7N5O3, is an adduct of guanine with glyoxal. In the mol-ecule, the di-hydro-imidazole ring adopts a twisted conformation on the C-C bond, and the two hydroxyl groups lie on opposite sides of the mean plane of the ring. In the crystal, the mol-ecules are linked by N-H⋯O, O-H⋯N and N-H⋯N hydrogen bonds forming a three-dimensional framework. The crystal packing is reinforced by C-H⋯O hydrogen bonds and by offset π-π stacking of the purine ring systems of inversion related mol-ecules [inter-centroid distance = 3.4839 (12) Å].

Entities:  

Keywords:  crystal structure; framework structure; hydrogen bonding; purine derivative

Year:  2016        PMID: 27536400      PMCID: PMC4971859          DOI: 10.1107/S2056989016009087

Source DB:  PubMed          Journal:  Acta Crystallogr E Crystallogr Commun


Chemical context

Purine are essential ingredients of various compounds, for example two of the five bases in nucleic acids, adenine and guanine, are purines. Purine derivatives have been developed as inhibitors of cyclin-dependent kinase (Sausville, 2002 ▸), and as anti­parasitic (Braga et al., 2007 ▸; Yadav et al., 2004 ▸), anti­tumor (Prekupec et al., 2003 ▸; Trávníček et al., 2001 ▸), anti­radical (Klanicová et al., 2010 ▸) and anti­viral (Manikowski et al., 2005 ▸) drugs. The synthesis and the cancerostatic and anti­viral activities of the title compound were reported on many years ago (Shapiro et al., 1969 ▸). Its crystal structure has not been reported to date, and as the conformation of a biologically active mol­ecule is crucial to its activity we undertook the structure analysis of the title compound, which we report on herein.

Structural commentary

The mol­ecular structure of title compound is depicted in Fig. 1 ▸. The C1—O1 bond length of 1.220 (2) Å shows typical double-bond character, and is coplanar with the purine moiety for their aromatic nature. The non-aromatic five-membered ring (N1/C7/C6/N5/C2) adopts a twisted conformation on the C6—C7 bond. The two hydroxyl groups lie on opposite sides of the ring mean plane with an O2—C7—C6—O3 torsion angle of 114.8 (2)°.
Figure 1

The mol­ecular structure of the title compound, with atom labelling. Displacement ellipsoids are drawn at the 50% probability level.

Supra­molecular features

In the crystal, mol­ecules are also linked via O—H⋯N and N—H⋯O hydrogen bonds, forming layers lying parallel to the ab plane (Table 1 ▸ and Fig. 2 ▸). The layers are linked by N—H⋯O hydrogen bonds, forming a three-dimensional framework (Table 1 ▸ and Fig. 3 ▸). Within the framework there are also C—H⋯O hydrogen bonds present (Table 1 ▸), and inversion-related mol­ecules are linked by offset π–π inter­actions involving the five-membered ring and the six-membered ring of the purine moieties [Cg2⋯Cg3i = 3.4839 (12) Å, inter­planar distance = 3.311 (1) Å, slippage = 1.112 Å; Cg2 and Cg3 are the centroids of the N3/C4/C3/N4/C5 and N1/C1/C4/C3/N2/C2 rings, respectively; symmetry code: (i) −x, −y, −z + 2].
Table 1

Hydrogen-bond geometry (Å, °)

D—H⋯A D—HH⋯A DA D—H⋯A
O2—H2⋯N2i 0.822.032.850 (2)178
O3—H3⋯N2ii 0.822.212.947 (2)150
N4—H4⋯O2iii 0.861.952.791 (2)167
N5—H5⋯N3iv 0.862.002.837 (2)166
C5—H5A⋯O3v 0.932.503.133 (8)126
C7—H7⋯O1vi 0.982.513.449 (2)161

Symmetry codes: (i) ; (ii) ; (iii) ; (iv) ; (v) ; (vi) .

Figure 2

A view along the c axis of the crystal packing of the title compound. The hydrogen bonds are shown as dashed lines (see Table 1 ▸).

Figure 3

A view along the b axis of the crystal packing of the title compound. The hydrogen bonds are shown as dashed lines (see Table 1 ▸).

Database survey

A search of the Cambridge Structural Database (CSD, Version 5.37, update May 2016; Groom et al., 2016 ▸) for 1,9-di­hydro-6H-6-one as substructure, gave 61 hits. Many of these compounds concern guanine and guaninium and some metal complexes, but none involve a fused third ring. The structure of the title compound has not been reported previously.

Synthesis and crystallization

The title compound was synthesized according to a literature method (Dey & Garner, 2000 ▸): An aqueous solution (1 l) of glyoxal monohydrate (8.71 g, 0.18 mol), guanine (1.55g, 0.01 mol) and a small amount of acetic acid was stirred for 24 h at 333 K. Then the excess water was removed by rotary evaporation and 250 ml of THF was added under stirring. The white suspension that formed was suction-filtered and washed with THF. The product was obtained as white powder after drying at 313 K. Colourless block-shaped crystals suitable for X-ray diffraction were obtained by recrystallization of the powder in a DMF/ethanol/water (v/v/v = 1/2/2) medium.

Refinement

Crystal data, data collection and structure refinement details are summarized in Table 2 ▸. All of the H atoms were positioned with idealized geometry and refined as riding: O—H = 0.82 Å, N—H = 0.86 Å and C—H = 0.93–0.98 Å, with U iso(H) = 1.2U eq(C) and 1.5U eq(O,N).
Table 2

Experimental details

Crystal data
Chemical formulaC7H7N5O3
M r 209.18
Crystal system, space groupTriclinic, P
Temperature (K)295
a, b, c (Å)6.8925 (4), 7.6352 (4), 8.0605 (6)
α, β, γ (°)95.063 (5), 105.135 (6), 107.647 (5)
V3)383.69 (4)
Z 2
Radiation typeCu Kα
μ (mm−1)1.26
Crystal size (mm)0.20 × 0.18 × 0.16
 
Data collection
DiffractometerAgilent Xcalibur, Eos, Gemini
Absorption correctionMulti-scan (CrysAlis PRO; Agilent, 2012)
T min, T max 0.52, 0.82
No. of measured, independent and observed [I > 2σ(I)] reflections2506, 1499, 1335
R int 0.033
(sin θ/λ)max−1)0.622
 
Refinement
R[F 2 > 2σ(F 2)], wR(F 2), S 0.057, 0.180, 1.00
No. of reflections1499
No. of parameters138
H-atom treatmentH-atom parameters constrained
Δρmax, Δρmin (e Å−3)0.67, −0.40

Computer programs: CrysAlis PRO (Agilent, 2012 ▸), SHELXS97, SHELXL97 and SHELXTL (Sheldrick, 2008 ▸) and PLATON (Spek, 2009 ▸).

Crystal structure: contains datablock(s) I, global. DOI: 10.1107/S2056989016009087/xu5887sup1.cif Structure factors: contains datablock(s) I. DOI: 10.1107/S2056989016009087/xu5887Isup2.hkl Click here for additional data file. Supporting information file. DOI: 10.1107/S2056989016009087/xu5887Isup3.cml CCDC reference: 1469976 Additional supporting information: crystallographic information; 3D view; checkCIF report
C7H7N5O3Z = 2
Mr = 209.18F(000) = 216
Triclinic, P1Dx = 1.811 Mg m3
Hall symbol: -P 1Cu Kα radiation, λ = 1.54178 Å
a = 6.8925 (4) ÅCell parameters from 1705 reflections
b = 7.6352 (4) Åθ = 7.0–73.5°
c = 8.0605 (6) ŵ = 1.26 mm1
α = 95.063 (5)°T = 295 K
β = 105.135 (6)°Block, colorless
γ = 107.647 (5)°0.20 × 0.18 × 0.16 mm
V = 383.69 (4) Å3
Agilent Xcalibur, Eos, Gemini diffractometer1499 independent reflections
Radiation source: Enhance (Cu) X-ray Source1335 reflections with I > 2σ(I)
Graphite monochromatorRint = 0.033
Detector resolution: 5.3031 pixels mm-1θmax = 73.7°, θmin = 5.8°
ω scansh = −8→8
Absorption correction: multi-scan (CrysAlis PRO; Agilent, 2012)k = −9→7
Tmin = 0.52, Tmax = 0.82l = −10→9
2506 measured reflections
Refinement on F2Primary atom site location: structure-invariant direct methods
Least-squares matrix: fullSecondary atom site location: difference Fourier map
R[F2 > 2σ(F2)] = 0.057Hydrogen site location: inferred from neighbouring sites
wR(F2) = 0.180H-atom parameters constrained
S = 1.00w = 1/[σ2(Fo2) + (0.1404P)2 + 0.079P] where P = (Fo2 + 2Fc2)/3
1499 reflections(Δ/σ)max < 0.001
138 parametersΔρmax = 0.67 e Å3
0 restraintsΔρmin = −0.40 e Å3
Experimental. CrysAlis Pro, Agilent Technologies, Version 1.171.35.21 (release 20-01-2012 CrysAlis171 .NET) (compiled Jan 23 2012,18:06:46) Empirical absorption correction using spherical harmonics, implemented in SCALE3 ABSPACK scaling algorithm.
Geometry. All esds (except the esd in the dihedral angle between two l.s. planes) are estimated using the full covariance matrix. The cell esds are taken into account individually in the estimation of esds in distances, angles and torsion angles; correlations between esds in cell parameters are only used when they are defined by crystal symmetry. An approximate (isotropic) treatment of cell esds is used for estimating esds involving l.s. planes.
Refinement. Refinement of F2 against ALL reflections. The weighted R-factor wR and goodness of fit S are based on F2, conventional R-factors R are based on F, with F set to zero for negative F2. The threshold expression of F2 > 2sigma(F2) is used only for calculating R-factors(gt) etc. and is not relevant to the choice of reflections for refinement. R-factors based on F2 are statistically about twice as large as those based on F, and R- factors based on ALL data will be even larger.
xyzUiso*/Ueq
O10.1803 (3)−0.0561 (2)0.71668 (19)0.0330 (4)
O20.3726 (2)0.34594 (19)0.61681 (18)0.0278 (4)
H20.47250.43100.68620.042*
O3−0.0753 (2)0.4579 (2)0.6656 (2)0.0355 (4)
H3−0.10430.54340.71050.053*
N10.2147 (2)0.2403 (2)0.8339 (2)0.0222 (4)
N20.2866 (3)0.3571 (2)1.1379 (2)0.0234 (4)
N30.2741 (3)−0.1191 (2)1.1004 (2)0.0267 (4)
N40.3297 (3)0.1187 (2)1.3093 (2)0.0254 (4)
H40.35630.18021.41190.031*
N50.2310 (3)0.5316 (2)0.9134 (2)0.0278 (4)
H50.26650.63840.97890.033*
C10.2159 (3)0.0573 (2)0.8471 (3)0.0227 (5)
C20.2459 (3)0.3764 (2)0.9729 (2)0.0217 (5)
C30.2944 (3)0.1830 (2)1.1558 (2)0.0212 (4)
C40.2612 (3)0.0354 (2)1.0264 (3)0.0226 (5)
C50.3142 (3)−0.0636 (3)1.2673 (3)0.0277 (5)
H5A0.3306−0.14021.34960.033*
C60.1474 (3)0.4966 (3)0.7242 (3)0.0245 (5)
H60.22270.59990.67520.029*
C70.1903 (3)0.3160 (3)0.6712 (2)0.0232 (5)
H70.06530.23000.57930.028*
U11U22U33U12U13U23
O10.0427 (8)0.0254 (8)0.0294 (8)0.0170 (6)0.0067 (6)−0.0085 (6)
O20.0276 (7)0.0275 (7)0.0277 (7)0.0082 (6)0.0123 (6)−0.0061 (5)
O30.0370 (8)0.0364 (9)0.0395 (9)0.0203 (7)0.0142 (7)0.0028 (7)
N10.0276 (8)0.0173 (8)0.0235 (8)0.0109 (6)0.0088 (6)−0.0023 (6)
N20.0298 (8)0.0183 (8)0.0239 (8)0.0102 (6)0.0106 (7)−0.0020 (6)
N30.0307 (8)0.0173 (8)0.0331 (9)0.0099 (6)0.0106 (7)0.0008 (6)
N40.0315 (8)0.0225 (8)0.0242 (8)0.0107 (7)0.0112 (6)0.0002 (6)
N50.0421 (10)0.0175 (8)0.0264 (8)0.0148 (7)0.0109 (7)−0.0016 (6)
C10.0224 (8)0.0172 (9)0.0276 (10)0.0078 (7)0.0073 (7)−0.0038 (7)
C20.0233 (8)0.0172 (8)0.0248 (9)0.0071 (7)0.0093 (7)−0.0027 (7)
C30.0213 (8)0.0160 (9)0.0269 (9)0.0069 (6)0.0095 (7)−0.0007 (7)
C40.0233 (8)0.0162 (8)0.0281 (10)0.0073 (7)0.0086 (7)−0.0014 (7)
C50.0323 (10)0.0212 (10)0.0313 (10)0.0115 (8)0.0102 (8)0.0025 (7)
C60.0310 (9)0.0201 (9)0.0270 (10)0.0117 (7)0.0131 (8)0.0033 (7)
C70.0259 (9)0.0202 (9)0.0237 (9)0.0088 (7)0.0084 (7)−0.0018 (7)
O1—C11.221 (2)N4—C31.361 (3)
O2—C71.398 (2)N4—C51.367 (2)
O2—H20.8200N4—H40.8600
O3—C61.410 (2)N5—C21.339 (3)
O3—H30.8200N5—C61.450 (2)
N1—C21.384 (2)N5—H50.8600
N1—C11.413 (2)C1—C41.433 (3)
N1—C71.470 (2)C3—C41.386 (2)
N2—C21.316 (2)C5—H5A0.9300
N2—C31.365 (2)C6—C71.543 (2)
N3—C51.304 (3)C6—H60.9800
N3—C41.384 (2)C7—H70.9800
C7—O2—H2109.5N4—C3—C4106.17 (16)
C6—O3—H3109.5N2—C3—C4128.41 (18)
C2—N1—C1125.05 (16)N3—C4—C3109.67 (17)
C2—N1—C7110.23 (15)N3—C4—C1130.23 (17)
C1—N1—C7124.65 (15)C3—C4—C1120.08 (17)
C2—N2—C3111.14 (15)N3—C5—N4113.27 (18)
C5—N3—C4104.69 (16)N3—C5—H5A123.4
C3—N4—C5106.20 (16)N4—C5—H5A123.4
C3—N4—H4126.9O3—C6—N5112.28 (16)
C5—N4—H4126.9O3—C6—C7107.73 (15)
C2—N5—C6111.39 (14)N5—C6—C7102.64 (14)
C2—N5—H5124.3O3—C6—H6111.3
C6—N5—H5124.3N5—C6—H6111.3
O1—C1—N1120.75 (18)C7—C6—H6111.3
O1—C1—C4129.30 (18)O2—C7—N1111.34 (15)
N1—C1—C4109.95 (15)O2—C7—C6114.01 (15)
N2—C2—N5125.43 (16)N1—C7—C6101.82 (14)
N2—C2—N1125.33 (17)O2—C7—H7109.8
N5—C2—N1109.23 (16)N1—C7—H7109.8
N4—C3—N2125.38 (16)C6—C7—H7109.8
C2—N1—C1—O1177.72 (17)N2—C3—C4—N3−177.14 (17)
C7—N1—C1—O1−5.4 (3)N4—C3—C4—C1179.03 (16)
C2—N1—C1—C4−1.9 (2)N2—C3—C4—C11.3 (3)
C7—N1—C1—C4175.00 (15)O1—C1—C4—N3−1.0 (3)
C3—N2—C2—N5−179.08 (18)N1—C1—C4—N3178.54 (17)
C3—N2—C2—N1−0.1 (3)O1—C1—C4—C3−179.13 (19)
C6—N5—C2—N2−169.71 (17)N1—C1—C4—C30.4 (2)
C6—N5—C2—N111.1 (2)C4—N3—C5—N4−0.3 (2)
C1—N1—C2—N21.8 (3)C3—N4—C5—N30.6 (2)
C7—N1—C2—N2−175.41 (17)C2—N5—C6—O395.18 (19)
C1—N1—C2—N5−179.00 (16)C2—N5—C6—C7−20.2 (2)
C7—N1—C2—N53.7 (2)C2—N1—C7—O2106.35 (17)
C5—N4—C3—N2177.11 (17)C1—N1—C7—O2−70.9 (2)
C5—N4—C3—C4−0.7 (2)C2—N1—C7—C6−15.51 (18)
C2—N2—C3—N4−178.80 (17)C1—N1—C7—C6167.22 (16)
C2—N2—C3—C4−1.5 (3)O3—C6—C7—O2141.81 (16)
C5—N3—C4—C3−0.2 (2)N5—C6—C7—O2−99.53 (18)
C5—N3—C4—C1−178.47 (19)O3—C6—C7—N1−98.19 (17)
N4—C3—C4—N30.6 (2)N5—C6—C7—N120.48 (18)
D—H···AD—HH···AD···AD—H···A
O2—H2···N2i0.822.032.850 (2)178
O3—H3···N2ii0.822.212.947 (2)150
N4—H4···O2iii0.861.952.791 (2)167
N5—H5···N3iv0.862.002.837 (2)166
C5—H5A···O3v0.932.503.133 (8)126
C7—H7···O1vi0.982.513.449 (2)161
  10 in total

1.  Synthesis and biological evaluation of some 6-substituted purines.

Authors:  Fernanda Gambogi Braga; Elaine Soares Coimbra; Magnum de Oliveira Matos; Arturene Maria Lino Carmo; Marisa Damato Cancio; Adilson David da Silva
Journal:  Eur J Med Chem       Date:  2006-12-06       Impact factor: 6.514

2.  A short history of SHELX.

Authors:  George M Sheldrick
Journal:  Acta Crystallogr A       Date:  2007-12-21       Impact factor: 2.290

Review 3.  Complexities in the development of cyclin-dependent kinase inhibitor drugs.

Authors:  Edward A Sausville
Journal:  Trends Mol Med       Date:  2002       Impact factor: 11.951

4.  Synthesis of tert-butoxycarbonyl (Boc)-protected purines.

Authors:  S Dey; P Garner
Journal:  J Org Chem       Date:  2000-11-03       Impact factor: 4.354

5.  Preparation, physicochemical properties and biological activity of copper(II) complexes with 6-(2-chlorobenzylamino)purine (HL1) or 6-(3-chlorobenzylamino)purine (HL2). The single-crystal X-ray structure of.

Authors:  Z Trávnícek; M Malon; Z Sindelál; K Dolezal; J Rolcík; V Krystof; M Strnad; J Marek
Journal:  J Inorg Biochem       Date:  2001-03       Impact factor: 4.155

6.  Inhibition of herpes simplex virus thymidine kinases by 2-phenylamino-6-oxopurines and related compounds: structure-activity relationships and antiherpetic activity in vivo.

Authors:  Andrzej Manikowski; Annalisa Verri; Andrea Lossani; Bryan M Gebhardt; Joseph Gambino; Federico Focher; Silvio Spadari; George E Wright
Journal:  J Med Chem       Date:  2005-06-02       Impact factor: 7.446

7.  Synthesis and biological evaluation of iodinated and fluorinated 9-(2-hydroxypropyl) and 9-(2-hydroxyethoxy)methyl purine nucleoside analogues.

Authors:  Svjetlana Prekupec; Drazenka Svedruzić; Tatjana Gazivoda; Draginja Mrvos-Sermek; Ante Nagl; Mira Grdisa; Kresimir Pavelić; Jan Balzarini; Erik De Clercq; Gerd Folkers; Leonardo Scapozza; Mladen Mintas; Silvana Raić-Malić
Journal:  J Med Chem       Date:  2003-12-18       Impact factor: 7.446

8.  On the reaction of guanine with glyoxal, pyruvaldehyde, and kethoxal, and the structure of the acylguanines. A new synthesis of N2-alkylguanines.

Authors:  R Shapiro; B I Cohen; S J Shiuey; H Maurer
Journal:  Biochemistry       Date:  1969-01       Impact factor: 3.162

9.  Structure validation in chemical crystallography.

Authors:  Anthony L Spek
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-01-20

10.  The Cambridge Structural Database.

Authors:  Colin R Groom; Ian J Bruno; Matthew P Lightfoot; Suzanna C Ward
Journal:  Acta Crystallogr B Struct Sci Cryst Eng Mater       Date:  2016-04-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.